KNG1 and acrodermatitis enteropathica: Our diagnostic score, if confirmed in a larger cohort of patients, could therefore be used in a therapeutic trial to ensure the inclusion of patients with AE attacks whose mechanism is bradykinin and not mast cell-mediated.